Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.

Fong JY, Pignata L, Goy PA, Kawabata KC, Lee SC, Koh CM, Musiani D, Massignani E, Kotini AG, Penson A, Wun CM, Shen Y, Schwarz M, Low DH, Rialdi A, Ki M, Wollmann H, Mzoughi S, Gay F, Thompson C, Hart T, Barbash O, Luciani GM, Szewczyk MM, Wouters BJ, Delwel R, Papapetrou EP, Barsyte-Lovejoy D, Arrowsmith CH, Minden MD, Jin J, Melnick A, Bonaldi T, Abdel-Wahab O, Guccione E.

Cancer Cell. 2019 Aug 12;36(2):194-209.e9. doi: 10.1016/j.ccell.2019.07.003.

PMID:
31408619
2.

Modeling blood diseases with human induced pluripotent stem cells.

Georgomanoli M, Papapetrou EP.

Dis Model Mech. 2019 Jun 4;12(6). pii: dmm039321. doi: 10.1242/dmm.039321. Review.

3.

Therapeutic discovery for marrow failure with MDS predisposition using pluripotent stem cells.

Ruiz-Gutierrez M, Bölükbaşı ÖV, Alexe G, Kotini AG, Ballotti K, Joyce CE, Russell DW, Stegmaier K, Myers K, Novina CD, Papapetrou EP, Shimamura A.

JCI Insight. 2019 Apr 30;5. pii: 125157. doi: 10.1172/jci.insight.125157.

4.

Modeling myeloid malignancies with patient-derived iPSCs.

Papapetrou EP.

Exp Hematol. 2019 Mar;71:77-84. doi: 10.1016/j.exphem.2018.11.006. Epub 2018 Nov 24. Review.

PMID:
30481543
5.

Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs.

Chang CJ, Kotini AG, Olszewska M, Georgomanoli M, Teruya-Feldstein J, Sperber H, Sanchez R, DeVita R, Martins TJ, Abdel-Wahab O, Bradley RK, Papapetrou EP.

Stem Cell Reports. 2018 May 8;10(5):1610-1624. doi: 10.1016/j.stemcr.2018.03.020. Epub 2018 Apr 19.

6.

Publisher Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.

Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang CJ, Papapetrou EP, He C, Elemento O, Huangfu D.

Nat Genet. 2018 May;50(5):764. doi: 10.1038/s41588-017-0024-5.

PMID:
29255266
7.

Author Correction: TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.

Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang CJ, Papapetrou EP, He C, Elemento O, Huangfu D.

Nat Genet. 2018 May;50(5):764. doi: 10.1038/s41588-017-0025-4.

PMID:
29255265
8.

TET proteins safeguard bivalent promoters from de novo methylation in human embryonic stem cells.

Verma N, Pan H, Doré LC, Shukla A, Li QV, Pelham-Webb B, Teijeiro V, González F, Krivtsov A, Chang CJ, Papapetrou EP, He C, Elemento O, Huangfu D.

Nat Genet. 2018 Jan;50(1):83-95. doi: 10.1038/s41588-017-0002-y. Epub 2017 Dec 4. Erratum in: Nat Genet. 2017 Dec 18;:. Nat Genet. 2017 Dec 18;:.

9.

Gene and Cell Therapy for β-Thalassemia and Sickle Cell Disease with Induced Pluripotent Stem Cells (iPSCs): The Next Frontier.

Papapetrou EP.

Adv Exp Med Biol. 2017;1013:219-240. doi: 10.1007/978-1-4939-7299-9_9.

PMID:
29127683
10.

Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Kotini AG, Chang CJ, Chow A, Yuan H, Ho TC, Wang T, Vora S, Solovyov A, Husser C, Olszewska M, Teruya-Feldstein J, Perumal D, Klimek VM, Spyridonidis A, Rampal RK, Silverman L, Reddy EP, Papaemmanuil E, Parekh S, Greenbaum BD, Leslie CS, Kharas MG, Papapetrou EP.

Cell Stem Cell. 2017 Mar 2;20(3):315-328.e7. doi: 10.1016/j.stem.2017.01.009. Epub 2017 Feb 16.

11.

Patient-derived induced pluripotent stem cells in cancer research and precision oncology.

Papapetrou EP.

Nat Med. 2016 Dec 6;22(12):1392-1401. doi: 10.1038/nm.4238. Erratum in: Nat Med. 2019 May;25(5):861.

12.

LiPS-A3S, a human genomic site for robust expression of inserted transgenes.

Kotini AG, Sadelain M, Papapetrou EP.

Mol Ther Nucleic Acids. 2016 Nov 29;5(11):e394. doi: 10.1038/mtna.2016.99.

13.

Induced pluripotent stem cells, past and future.

Papapetrou EP.

Science. 2016 Sep 2;353(6303):991-992. No abstract available.

14.

Gene Insertion Into Genomic Safe Harbors for Human Gene Therapy.

Papapetrou EP, Schambach A.

Mol Ther. 2016 Apr;24(4):678-84. doi: 10.1038/mt.2016.38. Epub 2016 Feb 12. Review.

15.

Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene.

Kotini AG, de Stanchina E, Themeli M, Sadelain M, Papapetrou EP.

Mol Ther Nucleic Acids. 2016 Feb 2;5:e284. doi: 10.1038/mtna.2015.57.

16.

Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells.

Kotini AG, Chang CJ, Boussaad I, Delrow JJ, Dolezal EK, Nagulapally AB, Perna F, Fishbein GA, Klimek VM, Hawkins RD, Huangfu D, Murry CE, Graubert T, Nimer SD, Papapetrou EP.

Nat Biotechnol. 2015 Jun;33(6):646-55. doi: 10.1038/nbt.3178. Epub 2015 Mar 23.

17.

The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells.

Perna F, Vu LP, Themeli M, Kriks S, Hoya-Arias R, Khanin R, Hricik T, Mansilla-Soto J, Papapetrou EP, Levine RL, Studer L, Sadelain M, Nimer SD.

Stem Cell Reports. 2015 Apr 14;4(4):658-69. doi: 10.1016/j.stemcr.2015.02.003. Epub 2015 Mar 5.

18.

A cell engineering strategy to enhance the safety of stem cell therapies.

Oricchio E, Papapetrou EP, Lafaille F, Ganat YM, Kriks S, Ortega-Molina A, Mark WH, Teruya-Feldstein J, Huse JT, Reuter V, Sadelain M, Studer L, Wendel HG.

Cell Rep. 2014 Sep 25;8(6):1677-1685. doi: 10.1016/j.celrep.2014.08.039. Epub 2014 Sep 18.

19.

CARs Move To the Fast Lane.

Davila ML, Papapetrou EP.

Mol Ther. 2014 Mar;22(3):477-478. doi: 10.1038/mt.2014.8. Epub 2016 Dec 6. No abstract available.

20.

Transcriptional activation by Oct4 is sufficient for the maintenance and induction of pluripotency.

Hammachi F, Morrison GM, Sharov AA, Livigni A, Narayan S, Papapetrou EP, O'Malley J, Kaji K, Ko MS, Ptashne M, Brickman JM.

Cell Rep. 2012 Feb 23;1(2):99-109. doi: 10.1016/j.celrep.2011.12.002. Epub 2012 Feb 16.

21.

FA iPS: correction or reprogramming first?

Papapetrou EP.

Blood. 2012 Jun 7;119(23):5341-2. doi: 10.1182/blood-2012-04-417246. No abstract available.

22.

Safe harbours for the integration of new DNA in the human genome.

Sadelain M, Papapetrou EP, Bushman FD.

Nat Rev Cancer. 2011 Dec 1;12(1):51-8. doi: 10.1038/nrc3179. Review.

PMID:
22129804
23.

Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites.

Papapetrou EP, Sadelain M.

Nat Protoc. 2011 Aug 4;6(9):1274-89. doi: 10.1038/nprot.2011.362.

PMID:
21886096
24.

Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector.

Papapetrou EP, Sadelain M.

Nat Protoc. 2011 Aug 4;6(9):1251-73. doi: 10.1038/nprot.2011.374.

PMID:
21886095
25.

Tacrolimus and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: An interaction study in CYP3A5 non-expressors, renal transplant recipients.

Katsakiori PF, Papapetrou EP, Goumenos DS, Nikiforidis GC, Flordellis CS.

Indian J Pharmacol. 2011 Jul;43(4):385-8. doi: 10.4103/0253-7613.83106.

26.

miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells.

Kim H, Lee G, Ganat Y, Papapetrou EP, Lipchina I, Socci ND, Sadelain M, Studer L.

Cell Stem Cell. 2011 Jun 3;8(6):695-706. doi: 10.1016/j.stem.2011.04.002.

27.

A method to sequence and quantify DNA integration for monitoring outcome in gene therapy.

Brady T, Roth SL, Malani N, Wang GP, Berry CC, Leboulch P, Hacein-Bey-Abina S, Cavazzana-Calvo M, Papapetrou EP, Sadelain M, Savilahti H, Bushman FD.

Nucleic Acids Res. 2011 Jun;39(11):e72. doi: 10.1093/nar/gkr140. Epub 2011 Mar 16.

28.

A bioinformatic assay for pluripotency in human cells.

Müller FJ, Schuldt BM, Williams R, Mason D, Altun G, Papapetrou EP, Danner S, Goldmann JE, Herbst A, Schmidt NO, Aldenhoff JB, Laurent LC, Loring JF.

Nat Methods. 2011 Apr;8(4):315-7. doi: 10.1038/nmeth.1580. Epub 2011 Mar 6.

29.

Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells.

Papapetrou EP, Lee G, Malani N, Setty M, Riviere I, Tirunagari LM, Kadota K, Roth SL, Giardina P, Viale A, Leslie C, Bushman FD, Studer L, Sadelain M.

Nat Biotechnol. 2011 Jan;29(1):73-8. doi: 10.1038/nbt.1717. Epub 2010 Dec 12.

30.

Reconstructing blood from induced pluripotent stem cells.

Papapetrou EP, Sadelain M.

F1000 Med Rep. 2010 Jun 16;2. pii: 44. doi: 10.3410/M2-44.

31.

Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis.

Yang JS, Maurin T, Robine N, Rasmussen KD, Jeffrey KL, Chandwani R, Papapetrou EP, Sadelain M, O'Carroll D, Lai EC.

Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15163-8. doi: 10.1073/pnas.1006432107. Epub 2010 Aug 10.

32.

Investigation of clinical interaction between omeprazole and tacrolimus in CYP3A5 non-expressors, renal transplant recipients.

Katsakiori PF, Papapetrou EP, Goumenos DS, Nikiforidis GC, Flordellis CS.

Ther Clin Risk Manag. 2010 Jun 24;6:265-9.

33.

Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.

Katsakiori PF, Papapetrou EP, Sakellaropoulos GC, Goumenos DS, Nikiforidis GC, Flordellis CS.

Int J Med Sci. 2010 May 11;7(2):94-100.

34.

A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells.

Papapetrou EP, Korkola JE, Sadelain M.

Stem Cells. 2010 Feb;28(2):287-96. doi: 10.1002/stem.257.

35.

Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.

Lee G, Papapetrou EP, Kim H, Chambers SM, Tomishima MJ, Fasano CA, Ganat YM, Menon J, Shimizu F, Viale A, Tabar V, Sadelain M, Studer L.

Nature. 2009 Sep 17;461(7262):402-6. doi: 10.1038/nature08320. Epub 2009 Aug 19.

36.

Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation.

Papapetrou EP, Tomishima MJ, Chambers SM, Mica Y, Reed E, Menon J, Tabar V, Mo Q, Studer L, Sadelain M.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12759-64. doi: 10.1073/pnas.0904825106. Epub 2009 Jun 23.

37.

Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling.

Chambers SM, Fasano CA, Papapetrou EP, Tomishima M, Sadelain M, Studer L.

Nat Biotechnol. 2009 Mar;27(3):275-80. doi: 10.1038/nbt.1529. Epub 2009 Mar 1. Erratum in: Nat Biotechnol. 2009 May;27(5):485.

38.

Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras.

Papapetrou EP, Kovalovsky D, Beloeil L, Sant'angelo D, Sadelain M.

J Clin Invest. 2009 Jan;119(1):157-68. doi: 10.1172/JCI37216. Epub 2008 Dec 1.

39.

Genetic modification of hematopoietic stem cells with nonviral systems: past progress and future prospects.

Papapetrou EP, Zoumbos NC, Athanassiadou A.

Gene Ther. 2005 Oct;12 Suppl 1:S118-30. Review.

PMID:
16231044
40.

Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element.

Papapetrou EP, Ziros PG, Micheva ID, Zoumbos NC, Athanassiadou A.

Gene Ther. 2006 Jan;13(1):40-51.

PMID:
16094410

Supplemental Content

Loading ...
Support Center